SynAgile is currently in the process of developing DopaFuse®, which stands as the premier patient-friendly, non-invasive treatment for the continuous administration of levodopa and carbidopa. SynAgile was established by the remarkably successful duo of Adam Heller (CSO) and Ephraim Heller (CEO), both renowned for their extensive portfolio of more than 300 patents, a significant portion of which are presently in operation. Their notable achievements include the creation of AngioScore (acquired for $235 million) and TheraSense (which became publicly traded before being acquired for $1.2 billion). Adam Heller is also recognized as a co-creator of the first commercially available lithium thionyl chloride battery and a recipient of